Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Jun 2017

Li Xia, Yan Xiao, Guo Wenjian, Huang Xin, Huang Jiansong, Yu Mengxia, Ma Zhixin, Xu Yu, Huang ShuJuan, Li Chenying, Zhou Yile, Jin Jie

Abstract excerpt

Chidamide, a novel histone deacetylase inhibitor (HDACi), has been approved for treatment of T-cell lymphomas in multiple clinical trials. It has been demonstrated that chidamide can inhibit cell cycle, promote apoptosis and induce differentiation in leukemia cells, whereas its effect on acute myeloid leukemia (AML) patients with FLT3-ITD mutation has not been clarified. In this study, we found that chidamide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to Cytarabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to fms-Like Tyrosine Kinase 3

Share to G1 Phase

Share to Histone Deacetylase Inhibitors

Share to Lymphoma, T-Cell

Share to Resting Phase, Cell Cycle

Source

Identifiers

PMID: 28419965
DOI: 10.1016/j.biopha.2017.04.037

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.PMID 28419965Read ↗

HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway.Semantic proximity Read ↗

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancySemantic proximity Read ↗

Synergistic Effect of Chidamide and Venetoclax on Apoptosis in Acute Myeloid Leukemia Cells and Its MechanismSemantic proximity Read ↗

RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.Semantic proximity Read ↗

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanismSemantic proximity Read ↗

HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathwaySemantic proximity Read ↗

Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective studySemantic proximity Read ↗

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.Semantic proximity Read ↗

Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).Semantic proximity Read ↗

Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.Semantic proximity Read ↗

Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.Semantic proximity Read ↗

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.